Format

Send to

Choose Destination
Front Oncol. 2017 Aug 11;7:169. doi: 10.3389/fonc.2017.00169. eCollection 2017.

Radiation Therapy in Extensive Stage Small Cell Lung Cancer.

Author information

1
BioIRC Centre for Biomedical Research, BioIRC, Kragujevac, Serbia.
2
Hospital Clínico Universitario, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
3
East Slovakia Institute of Oncology, Louis Pasteur University Hospital, Kosice, Slovakia.
4
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
5
Hospital Clínic de Barcelona, Barcelona, Spain.

Abstract

Lung cancer is the major cancer killer in the Western world, with the small cell lung cancer (SCLC) representing around 15-20% of all lung cancers. Extensive disease small cell lung cancer (ED SCLC) is found in approximately two-thirds of all cases, composed of both metastatic (M1) and non-metastatic (but presumably with tumor burden too large for locoregional-only approach) variant. Standard treatment options involve chemotherapy (CHT) over the past several decades. Radiation therapy (RT) had mostly been used in palliation of locoregional and/or metastatic disease. In contrast to its established role in treating metastatic disease, thoracic RT (TRT) had never been established as important part of the treatment aspects in this setting. In the past two decades, thoracic oncologists have witnessed wide introduction of modern RT and CHT aspects in ED SCLC, which led to more frequent use of RT and rise in the number of clinical studies. Since the pivotal study of Jeremic et al., who were the first to show importance of TRT in ED SCLC, a number of single-institutional studies have reconfirmed this observation, while recent prospective randomized trials (CREST and RTOG 0937) brought more substance to this issue. Similarly, the issue of prophylactic cranial irradiation was investigated in EORTC and the Japanese study, respectively, bringing somewhat conflicting results and calling for additional research in this setting. Future studies in ED SCLC could incorporate questions of RT dose and fractionation as well as the number of CHT cycles and type of combined Rt-CHT (sequential vs concurrent).

KEYWORDS:

chemotherapy; extensive disease; prophylactic cranial irradiation; small cell lung cancer; thoracic radiotherapy

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center